7th Jan 2016 08:52
LONDON (Alliance News) - SwissRed AG, in collaboration with London-listed Biofrontera AG, has received European CE marking for its IndoorLux illumination system for treatment of actinic keratoses, signifying that it has met safety, health, and environmental protection requirements.
According to Biofrontera, the clinical efficacy of the system was demonstrated using Biofrontera's photodynamic therapy drug Ameluz.
The pair said Thursday they will now collaborate in marketing the IndoorLux system. Ameluz is already approved as a prescription drug in the EU and Switzerland, and its market approval for the US is expected to follow in mid-2016.
"Our controlled PDT technology allows better medical care, at the same time minimising discomfort and morbidity," said Wilfried Priel, chairman of SwissRed AG.
Hermann Lübbert, chief executive of Biofrontera AG, added: "IndoorLux will provide dermatologists with a year-round platform to treat patients, thus providing a broader range of treatment options."
The CE certification allows SwissRed AG to market, install and service the Indoorlux PDT illumination system across the EU and Switzerland.
Shares in Biofrontera were untraded on Thursday morning, having last traded at 138.75 pence.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L